Author: James Love
Twenty groups write Congress, no fast track without public access to trade agreement negotiating texts
Twenty groups, including KEI, have written Congress, asking the Congress to provide public access to draft trade agreement texts and U.S. proposals throughout negotiations, and to specific that only agreements developed through such processes should obtain any expedited congressional consideration.
Among other things, the groups said:
St Jude’s influenza patents, with US government rights
St Jude holds 24 patents with influenza in the specification, that also disclose US government rights. Some of these were discussed here: /node/2188
PAT. NO. Title
1 8,574,592 Modified influenza virus for monitoring and improving vaccine efficiency
2 8,551,481 Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
3 8,309,099 DNA transfection system for the generation of negative strand RNA virus
Continue Reading
2009: CDC FOIA regarding intellectual property on avian flu intellectual property rights
Our 2009 FOIA request, and 42 pages of CDC emails debating what to give us.
/misc-docs/FOIA/14-01041-cdc-foia-frequest-2009.pdf
The February 17, 2015 cover letter from CDC.
/wp-content/uploads/CDC_17feb2015_FOIA_CoverLetter.pdf
The 184 page CDC foia response, which we received in February 2015. Note that we were particularly interested in the patent issues related to reverse genetics.
KEI Special 301 supplemental comments: Compulsory Licensing not restricted to “Emergencies” or “Measure of Last Resort”
At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: /ustr/special301).
KEI’s supplemental comments in USTR 301: Online pharmacies, parallel trade and counterfeit drugs
At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: /ustr/special301).
KEI’s Feb 27, 2015 Supplemental Comments to USTR Regarding Research and Development
At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: /ustr/special301).
KEI 2015 Special 301 Comments (filed February 6, 2015)
Attached are KEI’s February 6 comments to USTR on the 2015 Special 301.
Our 7 page submission begins with this:
KEI comments on India IP strategy
Attached are KEI’s January 30, 2015 comments on the India IP Policy.
/wp-content/uploads/KEI_30Jan2015_Comments_India_IPR_Policy.pdf
This is how the comments begin:
Knowledge Ecology International (KEI) has reviewed the document entitled “National IPR Policy” prepared by the IPR Think Tank. The document is surprisingly lacking in several key areas. In particular:
SEPTA class action suit on excessive pricing of Sovaldi, U.S. District Court for the Eastern District of Pennsylvania
Attached are:
1. The SEPTA the law suit.
2. A pessimistic 2011 OECD working paper on the weak competition remedies for excessive pricing in the United States.
3. A 2012 report on a 2011 OECD policy roundtable on excessive pricing